- Eurofins CDMO Alphora has launched an AI-powered software platform for high-throughput salt and co-crystal screening.
- The tool is now a core component of all solid-state screening programs and is designed to shorten timelines and reduce costs.
Eurofins CDMO Alphora has developed and launched an AI-powered software platform for high-throughput salt and co-crystal screening, now integrated as a core component of its solid-state screening programs. The machine learning tool was developed in collaboration with a local university and is designed to predict salt and co-crystal formation for active pharmaceutical ingredients and intermediates.
The software applies advanced predictive models to support solid form selection by reducing trial-and-error experimentation. According to the company, this approach shortens development timelines and lowers screening costs, enabling earlier, data-driven decision-making during drug substance development.
Eurofins CDMO Alphora’s solid-state research and development team supports customers throughout the salt and co-crystal development process, from data interpretation to experimental strategy. The team also addresses a broader range of solid-state challenges beyond salt and co-crystal screening.
Through collaboration across drug substance and drug product development functions, the CDMO provides integrated contract manufacturing and development solutions aimed at improving bioavailability and manufacturing process performance.
